Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
In the original sample, there was not significant difference in the clinical endpoints at week 52, but there was a trend for less increase in the MRI BOD and significantly less Gd‐enhancing lesions in the vitamin D arm than in the placebo arm at week 52.
Source: RESULTS. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Briefly, 66 RRMS patients aged 18 to 55 years with IFNb‐1b use for at least 1 months and no neutralizing antibodies to IFNb were detected and baseline 25(OH)D levels below 85 nmol/L, were randomized to either 20,000 IU of cholecalciferol (Swiss‐Caps), or identical placebo capsules, for 52 weeks.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Vitamin D supplementation and serum neurofilament light chain in interferon‐beta‐1b‐treated MS patients
Study design awaiting verification · Brain and Behavior · 2020
Original publication title
Vitamin D supplementation and serum neurofilament light chain in interferon‐beta‐1b‐treated MS patients
© 2020 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Serum neurofilament light chain (sNfL) is a promising biomarker of MS activity, progression, and treatment response. The aim of the present study was to address whether sNfL concentrations are affected by supplementation of vitamin D and correlate with disease activity in interferon‐beta‐1b (IFNb‐1b)‐treated Finnish MS.
Source: ObjectivesAbstract: What methods does the paper describe?
Serum samples were available of 32 participants of the Finnish vitamin D randomized controlled trial (17 vitamin D/15 placebo). Serum 25 hydroxyvitamin D was measured using radioimmunoassay and sNfL using single‐molecule array (Simoa). Correlation of sNfL with brain magnetic resonance imaging (MRI) activity, burden of disease (BOD, mm3), and disability was assessed at the study baseline and at 52 weeks.
Source: Materials and MethodsAbstract: Results
Serum NfL concentrations were similar in the patients randomized to high‐dose vitamin D and placebo at the study baseline and at month 12 follow‐up (p‐value). Concentrations of sNfL were higher in patients with Gadolinium‐enhancing lesions in brain MRI: median (95% CI) sNfL was 14.84 (9.9 to 42.5) pg/ml and 11.39 (8.9 to 13.2) pg/ml in patients without Gd+ lesions (p = .0144) and correlated with enhancing lesion volume (Pearson r = .36, p = .037) at the study baseline but not at week 52.
Serum NfL did not correlate with the MRI BOD or disability measured by expanded disability status scale and 25‐foot walk test.
Source: ResultsAbstract: Conclusion
In this small cohort of clinically stable IFN‐treated Finnish MS patients, sNfL levels were similarly low in patients supplemented with high‐dose vitamin D or placebo. Subclinical disease activity in MRI was associated with higher sNfL levels.
Source: ConclusionAuthors’ abstract
Abstract
Objectives
Serum neurofilament light chain (sNfL) is a promising biomarker of MS activity, progression, and treatment response. The aim of the present study was to address whether sNfL concentrations are affected by supplementation of vitamin D and correlate with disease activity in interferon‐beta‐1b (IFNb‐1b)‐treated Finnish MS.
Materials and Methods
Serum samples were available of 32 participants of the Finnish vitamin D randomized controlled trial (17 vitamin D/15 placebo). Serum 25 hydroxyvitamin D was measured using radioimmunoassay and sNfL using single‐molecule array (Simoa). Correlation of sNfL with brain magnetic resonance imaging (MRI) activity, burden of disease (BOD, mm3), and disability was assessed at the study baseline and at 52 weeks.
Results
Serum NfL concentrations were similar in the patients randomized to high‐dose vitamin D and placebo at the study baseline and at month 12 follow‐up (p‐value). Concentrations of sNfL were higher in patients with Gadolinium‐enhancing lesions in brain MRI: median (95% CI) sNfL was 14.84 (9.9 to 42.5) pg/ml and 11.39 (8.9 to 13.2) pg/ml in patients without Gd+ lesions (p = .0144) and correlated with enhancing lesion volume (Pearson r = .36, p = .037) at the study baseline but not at week 52.
Serum NfL did not correlate with the MRI BOD or disability measured by expanded disability status scale and 25‐foot walk test.
Conclusion
In this small cohort of clinically stable IFN‐treated Finnish MS patients, sNfL levels were similarly low in patients supplemented with high‐dose vitamin D or placebo. Subclinical disease activity in MRI was associated with higher sNfL levels.
Publication and source details
Original title: Vitamin D supplementation and serum neurofilament light chain in interferon‐beta‐1b‐treated MS patients
Katariina Hänninen; Olli Jääskeläinen; Sanna‐Kaisa Herukka; Merja Soilu‐Hänninen
Brain and Behavior · 2020
* CorrespondenceMerja Soilu‐Hänninen, Turku University Hospital Neurocenter, Turku University Hospital, Turku, Finland.
Email: merja.soilu-hanninen@tyks.fi
© 2020 The Authors. Brain and Behavior published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Bayer Schering 10.13039/501100006010
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T16:39:32.221812+00:00
DOI: 10.1002/brb3.1772 · PMC7507359